Though the FDA has requested no new data, the additional information reflects a major amendment to Rhythm’s supplemental new drug application (sNDA), allowing the FDA more time to go over the ...

Editor's note: this interview was originally published on BioPharmInternational.com.

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the MHRA for all four formulations of ...

Market opportunities lie in modernizing software development and validation approaches, emphasizing agility and continuous validation to meet changing needs, while ensuring compliance with FDA ...

Long before he found himself in the middle of a multibillion-dollar takeover battle for a coveted new weight-loss drug, Whit ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Donald Trump has signed deals with the pharma giants Novo Nordisk and Eli Lilly to lower the prices of antiobesity drugs and get more US citizens taking them. The deal will cover tirzepatide (Lilly’s ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

With an AI-led platform for drug discovery and a growing global client base, Medvolt AI is emerging as one of India’s most ...

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies ...

Q3 2025 Earnings Call November 6, 2025 4:30 PM ESTCompany ParticipantsStephen Silvestro - President & CEOEdward Stelmakh ...